Molecular Partners Ag (MOLN) Operating Leases (2020 - 2025)
Molecular Partners Ag (MOLN) posted quarterly Operating Leases of $4.6 million for Q4 2025, up 63.42% year-over-year from $2.8 million in Q4 2024, and up 513.75% quarter-over-quarter from $742852.5 in Q2 2025.
Molecular Partners Ag (MOLN) Operating Leases (2020 - 2025) Analysis & Trends
Molecular Partners Ag (MOLN) has reported Operating Leases for 6 consecutive years, with $4.6 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Operating Leases rose 63.42% year-over-year to $4.6 million; the TTM figure through Dec 2025 stood at $4.6 million (up 63.42% YoY), while the FY2025 annual figure was $4.6 million, up 63.42% from the prior year.
- Operating Leases climbed to $4.6 million in Q4 2025 per MOLN's latest filing, from $742852.5 in the prior quarter.
- Across five years, Operating Leases topped out at $6.5 million in Q4 2021 and bottomed at $742852.5 in Q2 2025.
- Historically, Operating Leases has averaged $3.7 million across 5 years, with a median of $4.1 million in 2023.
- On a YoY basis, Operating Leases climbed as much as 63.42% in 2025 and fell as far as 63.43% in 2025.
- Molecular Partners Ag's Operating Leases stood at $6.5 million in 2021, then declined by 23.13% to $5.0 million in 2022, then declined by 18.22% to $4.1 million in 2023, then sank by 32.24% to $2.8 million in 2024, then soared by 63.42% to $4.6 million in 2025.
- Business Quant data shows MOLN's Operating Leases at $4.6 million in Q4 2025, $742852.5 in Q2 2025, and $2.8 million in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.81 Bn | 130.96 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 86.07 Bn | 78.08 Bn | 3.93 Bn |
| 3 | Argenx Se | 65.47 Bn | 60.29 Bn | 1.37 Bn |
| 4 | Moderna | 55.64 Bn | 50.50 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.99 Bn | 36.89 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.68 Bn | 28.37 Bn | 992.69 Mn |
| 7 | BioNTech SE | 27.69 Bn | 9.29 Bn | 668.28 Mn |
| 8 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.36 Bn | 26.52 Bn | - |
| 10 | Molecular Partners Ag | 163.99 Mn | 163.99 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 4.56 Mn |
| Jun 30, 2025 | 742,852.49 |
| Dec 31, 2024 | 2.79 Mn |
| Jun 30, 2024 | 2.03 Mn |
| Dec 31, 2023 | 4.12 Mn |
| Jun 30, 2023 | 3.39 Mn |
| Dec 31, 2022 | 5.03 Mn |
| Jun 30, 2022 | 4.41 Mn |
| Dec 31, 2021 | 6.55 Mn |
| Dec 31, 2020 | 7.98 Mn |